shulz/E+ via Getty Images
Exicure (NASDAQ:XCUR) signed a memorandum of understanding with GPCR Therapeutics aimed at the acquisition of GPCR USA, a subsidiary of GPCR Therapeutics, as well as the technology transfer and joint research of GPCR Therapeutics’ current drug development pipelines.
Through this acquisition, Exicure plans to provide
2024-12-27 06:25:21
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2148612652/image_2148612652.jpg?io=getty-c-w750